Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

Moriwaki Toshikazu; Fukuoka Shota; Taniguchi Hiroya; Takashima Atsuo; Kumekawa Yusuke; Kajiwara Takeshi; Yamazaki Kentaro; Esaki Taito; Makiyama Chinatsu; Denda Tadamichi; Satake Hironaga; Suto Takeshi; Sugimoto Naotoshi; Enomoto Masanobu; Ishikawa Toshiaki; Kashiwada Tomomi; Sugiyama Masahiko; Komatsu Yoshito; Okuyama Hiroyuki; Baba Eishi; Sakai Daisuke; Watanabe Tomoki; Tamura Takao; Yamashita Kimihiro; Gosho Masahiko; Shimada Yasuhiro

首页> 外文期刊>The oncologist >Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

【24h】

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

机译：转移性结直肠癌难治性难治标准化疗的患者中较令吉的倾向评分分析（焦度）：日本结肠和直肠多中心观测研究的日本癌症学会

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThis study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment.

机译：背景技术将Regorafenib和Trifluridine / Tipiracil（TFTD）与转移结直肠癌（MCRC）的患者进行了比较了标准化疗的难治性的疗效，因为尽管它们临床认可，但仍然不清楚这两种药物中的哪一种应该用作初始治疗。

著录项

来源
《The oncologist》 |2018年第1期|共9页
作者
Moriwaki Toshikazu; Fukuoka Shota; Taniguchi Hiroya; Takashima Atsuo; Kumekawa Yusuke; Kajiwara Takeshi; Yamazaki Kentaro; Esaki Taito; Makiyama Chinatsu; Denda Tadamichi; Satake Hironaga; Suto Takeshi; Sugimoto Naotoshi; Enomoto Masanobu; Ishikawa Toshiaki; Kashiwada Tomomi; Sugiyama Masahiko; Komatsu Yoshito; Okuyama Hiroyuki; Baba Eishi; Sakai Daisuke; Watanabe Tomoki; Tamura Takao; Yamashita Kimihiro; Gosho Masahiko; Shimada Yasuhiro;
展开▼
作者单位

Univ Tsukuba Fac Med Div Gastroenterol 1-1-1 Tennodai Tsukuba Ibaraki 3058575 Japan;

Natl Canc Ctr Hosp East Dept Gastrointestinal Oncol Kashiwa Chiba Japan;

Aichi Canc Ctr Hosp Dept Clin Oncol Chikusa Ku Nagoya Aichi Japan;

Natl Canc Ctr Gastrointestinal Med Oncol Div Chuo Ku Tokyo Japan;

Saitama Canc Ctr Dept Gastroenterol Saitama Japan;

Shikoku Canc Ctr Natl Hosp Org Dept Gastrointestinal Med Oncol Matsuyama Ehime Japan;

Shizuoka Canc Ctr Div Gastrointestinal Oncol Shizuoka Japan;

Kyushu Natl Canc Ctr Dept Gastrointestinal &

Med Oncol Minami Ku Fukuoka Fukuoka Japan;

Kyushu Hosp Japan Community Healthcare Org Dept Hematol Oncol Kitakyushu Fukuoka Japan;

Chiba Canc Ctr Div Gastroenterol Chuo Ku Chiba Chiba Japan;

Gen Hosp Kobe City Med Ctr Dept Med Oncol Chuo Ku Kobe Hyogo Japan;

Yamagata Prefectural Cent Hosp Dept Gastroenterol Surg Yamagata Yamagata Japan;

Osaka Int Canc Inst Dept Med Oncol Chuo Ku Osaka Osaka Japan;

Tokyo Med &

Dent Univ Grad Sch Med &

Dent Dept Specialized Surgeries Tokyo Japan;

Saga Univ Fac Med Dept Internal Med Div Hematol Resp Med &

Oncol Saga Saga Japan;

Kyushu Univ Grad Sch Med Sci Dept Surg &

Sci Higashi Ku Fukuoka Fukuoka Japan;

Hokkaido Univ Hosp Canc Ctr Dept Canc Chemotherapy Kita Ku Sapporo Hokkaido Japan;

Kagawa Univ Fac Med Dept Clin Oncol Kagawa Japan;

Kyushu Univ Fac Med Sci Dept Comprehens Clin Oncol Higashi Ku Fukuoka Fukuoka Japan;

Osaka Univ Grad Sch Med Dept Frontier Sci Canc &

Chemotherapy Suita Osaka Japan;

Natl Def Med Coll Hosp Dept Surg Tokorozawa Saitama Japan;

Kindai Univ Fac Med Dept Med Oncol Sayama Osaka Japan;

Kobe Univ Grad Sch Med Dept Surg Div Gastrointestinal Surg Chuo Ku Kobe Hyogo Japan;

Univ Tsukuba Fac Med Dept Clin Trial &

Clin Epidemiol Tsukuba Ibaraki Japan;

Kochi Hlth Sci Ctr Clin Oncol Div Kochi Kochi Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Colorectal cancer; Propensity score; Regorafenib; TAS-102; Trifluridine; tipiracil;

机译：结肠直肠癌;倾向得分;regorafenib;TAS-102;TRIFLURIDINE;TIPIRACIL;

相似文献

外文文献
中文文献
专利

1. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study [J] . Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, The oncologist . 2018,第1期

机译：瑞格非尼与三氟吡啶/替吡拉西对标准化学疗法（REGOTAS）难以治疗的转移性结直肠癌患者的倾向得分分析：日本结肠癌和直肠癌多中心观察研究
2. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study [J] . TOSHIKAZU MORIWAKI, SHOTA FUKUOKA, HIROYA TANIGUCHI, The oncologist . 2018,第1期

机译：瑞格非尼与三氟吡啶/替吡拉西对标准化学疗法（REGOTAS）难以治疗的转移性结直肠癌患者的倾向得分分析：日本结肠癌和直肠癌多中心观察研究
3. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study [J] . Moriwaki Toshikazu, Fukuoka Shota, Taniguchi Hiroya, The oncologist . 2018,第1期

机译：转移性结直肠癌难治性难治标准化疗的患者中较令吉的倾向评分分析（焦度）：日本结肠和直肠多中心观测研究的日本癌症学会
4. Correlation study of (IL-17 , IL-17RA ) and some biochemical parameters with patients of iraq colorectal cancer after and before taking a dose of chemotherapy [C] . Mezher N. Moslem, A. F. Altaie International Conference on Materials Engineering and Science . 2020

机译：（IL-17，IL-17RA）与一些生物化学参数与伊拉克结肠直肠癌患者服用化疗的相关性研究
5. Symptom trajectories in patients with lung cancer, colorectal cancer, and lymphoma during chemotherapy and posttreatment: A latent growth curve analysis [D] . Brant, Jeannine Marie 2008

机译：肺癌，大肠癌和淋巴瘤患者化疗和治疗后的症状轨迹：潜在生长曲线分析
6. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study [O] . Toshikazu Moriwaki, *, Shota Fukuoka, 2018

机译：瑞格非尼与三氟吡啶/替吡拉西对标准化学疗法（REGOTAS）难以治疗的转移性结直肠癌患者的倾向得分分析：日本结肠癌和直肠癌多中心观察研究
7. Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) [O] . Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, 2021

机译：转移结直肠癌患者的Regorafenib和Trifluridine / TipiraciliL盐酸盐交叉施用的存活率：日本结肠和直肠多中心观测研究的日本癌症探索性分析（焦点）

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

摘要

著录项

相似文献

相关主题

期刊订阅